Compare ANDE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | NRIX |
|---|---|---|
| Founded | 1947 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | ANDE | NRIX |
|---|---|---|
| Price | $68.85 | $15.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $65.00 | $29.46 |
| AVG Volume (30 Days) | 285.0K | ★ 1.1M |
| Earning Date | 02-17-2026 | 01-28-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $11,595,817,000.00 | $83,980,000.00 |
| Revenue This Year | $6.52 | N/A |
| Revenue Next Year | $3.73 | $28.52 |
| P/E Ratio | $32.39 | ★ N/A |
| Revenue Growth | 2.19 | ★ 53.95 |
| 52 Week Low | $31.03 | $8.18 |
| 52 Week High | $70.06 | $22.50 |
| Indicator | ANDE | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 74.49 | 39.86 |
| Support Level | $67.30 | $15.33 |
| Resistance Level | $70.06 | $16.97 |
| Average True Range (ATR) | 1.83 | 1.04 |
| MACD | 0.29 | -0.18 |
| Stochastic Oscillator | 80.62 | 15.39 |
Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.